ORPHA:91140
Unspecified juvenile idiopathic arthritis
Also known as: Unspecified JIA
Publications
11
29.2th percentile
Trials
0
Interventional, condition-specific
Researchers
72
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Unspecified juvenile arthritis is a rare, pediatric, rheumatologic disease, a subtype of juvenile arthritis (JIA) characterized by arthritis of an unknown cause that persists for at least 6 weeks, and does not fulfill the criteria for any of the other JIA subtypes, or fulfills criteria for more than one of the other subtypes.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019607
- UMLS:C5680196
Additional Mondo synonyms (1)
unspecified JIA
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
11 matched papers (11 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 177 for broader category juvenile idiopathic arthritis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
11
11 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
11 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
11 in the last 10 years · high confidence · 29.2th percentile (publications denominator)
Phrase hits: 11 · MeSH hits: 0
Who's working on it?
72
Distinct author names in 11 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Aalto K1 paper · 2025
New Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
Papers in Europe PMC - 02Ahn JG1 paper · 2025
Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC - 03Alkilany R1 paper · 2022Papers in Europe PMC
- 04Anthony DD1 paper · 2022Papers in Europe PMC
- 05Backström M1 paper · 2025
Research Unit of Clinical Medicine, University of Oulu, Oulu, Finland.
Papers in Europe PMC - 06Bernasconi A1 paper · 2023
Department of Electronics, Information and Bioengineering, Politecnico di Milano, Via Ponzio 34/5, 20133, Milano, Italy. anna.bernasconi@polimi.it.
Papers in Europe PMC - 07Bukulmez H1 paper · 2022Papers in Europe PMC
- 08Canakoglu A1 paper · 2023
Department of Electronics, Information and Bioengineering, Politecnico di Milano, Via Ponzio 34/5, 20133, Milano, Italy.
Papers in Europe PMC - 09Chen HY1 paper · 2024
Department of Pediatrics, Cathay General Hospital Hsinchu Branch, Hsinchu, Taiwan.
Papers in Europe PMC - 10Chiang BL1 paper · 2024
Department of Pediatrics, National Taiwan University Hospital, No. 8 Chung-Shan South Road, Taipei, 100, Taiwan, ROC.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 177 trials are registered for juvenile idiopathic arthritis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
177 interventional trials matched juvenile idiopathic arthritis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: juvenile idiopathic arthritis
177
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07184450·RECRUITING·Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Conditions: Juvenile Dermatomyositis (JDM) · Polyarticular Juvenile Idiopathic Arthritis · Systemic Sclerosis (SSc) · Primary Sjogren's Syndrome·Matched via name phrase
- NCT06654882·RECRUITING·Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
Conditions: Polyarticular Course Juvenile Idiopathic Arthritis (JIA)·Matched via name phrase
- NCT03773965·RECRUITING·A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Conditions: Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT07553182·RECRUITING·OLE Study With Filgotinib in JIA
Conditions: Juvenile Idiopathic Arthritis (JIA)·Matched via name phrase
- NCT07087912·RECRUITING·Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Conditions: Rheumatoid Arthritis (RA) · Juvenile Idiopathic Arthritis (JIA) · Systemic Lupus Erythematosus (SLE) · Juvenile Systemic Lupus Erythematosus·Matched via name phrase
- NCT07699107·NOT YET RECRUITING·Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
Conditions: Juvenile Idiopathic Arthritis Associated Uveitis · Uveitis, Anterior·Matched via name phrase
- NCT07386587·ENROLLING BY INVITATION·Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis
Conditions: Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT06653634·RECRUITING·Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
Conditions: Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT07554495·RECRUITING·Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
Conditions: Polyarticular Course Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT07634354·NOT YET RECRUITING·Sarcopenia and Juvenile Idiopathic Arthritis
Conditions: Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT06888973·ENROLLING BY INVITATION·Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases
Conditions: Rheumatoid Arthritis · Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis · Ankylosing Spondylitis (AS)·Matched via name phrase
- NCT01962415·RECRUITING·Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Conditions: Primary Immunodeficiency (PID) · Congenital Bone Marrow Failure Syndromes · Inherited Metabolic Disorders (IMD) · Hereditary Anemias·Matched via name phrase
- NCT06376149·RECRUITING·M3-JIA: Making Mindfulness Matter for Children With JIA
Conditions: Juvenile Idiopathic Arthritis · Children · Mental Health · Mental Well-being·Matched via name phrase
- NCT06874608·RECRUITING·Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis
Conditions: Juvenile Idiopathic Arthritis (JIA)·Matched via name phrase
- NCT07661069·NOT YET RECRUITING·YOGA FOR CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS
Conditions: Juvenile Idiopathic Arthritis (JIA)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Unspecified juvenile idiopathic arthritis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Unspecified juvenile idiopathic arthritis" OR "Unspecified JIA"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Unspecified juvenile idiopathic arthritis" OR "Unspecified JIA"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"juvenile idiopathic arthritis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T03:57:59.302Z
